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This review has focused on important but less visible aspects of fibromyalgia (FM) with respect to the high 
impact of this disorder on patients and societies. FM is a common but challengeable illness. It is characterized 
by chronic widespread pain, which can be accompanied by other symptoms including fatigue, sleep 
disturbances, cognitive dysfunction, anxiety and depressive episodes. While our understanding of this 
debilitating disorder is limited, diagnosis and treatment of this condition is very difficult, even in the hands 
of experts. Due to the nature of disease, where patients experience invalidation by medical services, their 
families and societies regarding the recognition and management of disease, direct, indirect and immeasurable 
costs are considerable. These clinical and economic costs are comparable with other common diseases, such 
as diabetes, hypertension and osteoarthritis, but the latter usually receives much more attention from healthcare 
and non-healthcare resources. Present alarming data shows the grave and “iceberg-like” burden of FM despite 
the benign appearance of this disorder and highlights the urgent need both for greater awareness of the disease 
among medical services and societies, as well as for more research focused on easily used diagnostic methods 
and target specific treatment. (Korean J Pain 2015; 28: 169-176)
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INTRODUCTION
Fibromyalgia (FM) is a chronic disorder that is charac-
terized by chronic widespread pain and is generally accom-
panied by one or more concomitant symptoms, including 
fatigue, sleep disturbances, cognitive dysfunction, anxiety 
or/and depressive episodes, headache, abdominal pain or 
other somatic symptoms [1-3]. Up to 85% of patients with 
FM are women, typically of childbearing age or older [4].
It is one of the most common conditions seen in the 
general population and outpatient rheumatology practice 
[3,5,6]. In primary rheumatology clinics, referrals for FM 
comprise 14-20% of new visits making FM the second to 
third most common reason for appointments [3,7]. 
However, clinic attendees might represent only the tip of 
the iceberg of people with FM. Indeed, prevalence esti-
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mates of FM in the general population have ranged from 
approximately 1-11% to even more than 18% [2,8].
FM's definition and content has changed repeatedly in 
the 110 years of its existence. The most important change 
was the requirement for multiple tender points and ex-
tensive pain for diagnosis of this condition that arose in 
the 1980s (1990 American College of Rhematology classi-
fication criteria). These are features that were not required 
previously. By 2010, a second shift revised the definition 
of FM, so it came into being in the form of the preliminary 
2010 ACR criteria that excluded tender points, allowed less 
extensive pain, and placed reliance on patient-reported 
somatic symptoms and cognitive difficulties that had never 
been part of past definitions or content [3,9-14].
It seems the challenge for the diagnosis of FM will 
continue in the future until our knowledge about neuro-
biological mechanisms progresses.
On the other hand, FM is difficult to diagnose, and 
physician awareness of FM is relatively low despite the 
prevalence of the syndrome. Thus, it is not uncommon to 
see patients who have gone from doctor to doctor and who 
underwent multiple diagnostic tests, with a differential di-
agnosis that includes lupus erythematous, rheumatoid ar-
thritis, somatization and malingering [7,15].
FM was associated with high rates of many comorbid 
illnesses [16-19]. On average, FM claimants had claims for 
4.2 distinct comorbid conditions per year [16,19,20]. Notable 
is that the high prevalence of various medical and psychi-
atric comorbidities is not necessarily suggestive of an etio-
logical link between these conditions and FM. One ex-
planation may be that these patients had frequent visits 
by medical providers. More frequent visits may lead to op-
portunistic case finding and hence a higher prevalence of 
diagnosed medical and psychiatric comorbidities. Another 
theory is the difficulty in making a diagnosis of FM. 
Patients might receive a variety of other diagnoses as pos-
sible explanations for the overlapping symptoms patients 
possess, or it may suggest that the clinicians of these pa-
tients were not satisfied that this condition fully explained 
their symptoms [11,12,16,19]. 
Since FM is a common disorder with diverse manifes-
tations, under-diagnosis causes excessive testing and in-
appropriate treatment. The delay in diagnosis causes an 
economic burden on the healthcare system and frustration 
for patients and their families [11,21-24]. 
Medical care of FM and comorbidities are not only 
quite difficult, time consuming and costly, but this disorder 
also tends to be intractable. There is no reliable tool to 
predict treatment response in individual patients, and clin-
ical routine largely relies on trial and error [2]. Further-
more, the majority of patients have unmet needs other 
than widespread pain, including mood disorders, cognitive 
abnormality, sexual dysfunction and a lack of sociomedical 
acceptance - aspects that have a deep effect on their 
quality of life. 
Consequently, it is not surprising that the high impact 
of fibromyalgia on the quality of life of these subjects leads 
to poor health at home and work, loss of productivity due 
to absenteeism, presenteeism, unemployment, and disa-
bility. Consequently, this puts a strain on involved health-
care and non-healthcare resources [21,25,26].
Recent studies evaluated fibromyalgia-related direct 
and indirect costs [16,19,21,25-30]. Direct costs include 
medical and pharmacy costs, while indirect costs include 
the cost of disability and productivity loss, absenteeism, 
presenteeism, changes in employment status, and unpaid 
informal care. FM patients make 10 to 18 primary care ap-
pointments per year and are hospitalized on average once 
every 3 years [16,19,20,30]. Patients also reported missing 
0.4 to 3.0 days from work and being unable to complete 
3.6 to 35.4 hours of unpaid informal work due to FM, in-
cludingchild care, housework, yard work, or other daily ac-
tivities [30].
The mean annual cost per patient ranged US $2,274 
to $9,573 or even more in various studies depended on the 
severity of symptoms and rout of cost calculation 
[19,30,31].
Notably, indirect costs account for the majority of 
FM-related costs at all severity levels. More than 
three-quarters of total FM-related costs were attributable 
to lost productivity and disability [30,31]. 
Although various studies tried to calculate the direct 
and indirect cost of disease, it seems that estimation of 
real cost is very difficult and under-assessed. Patients 
with FM often require additional resources, such as unpaid 
assistance from family or paid caregivers and for help with 
independent daily activities [21,30]. Sick time at home and 
productivity when at work were not fully measured. Failure 
to properly account for comorbid conditions is another 
reason for the underestimation of the real costs of the dis-
ease [19].
Overall, it seems the clinical and economic burden of 
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the disease on societies is high so that FM is on the same 
level as other chronic diseases, such as diabetes or 
hypertension. Although, the latter usually receives much 
more attention from the healthcare and non-healthcare 
systems [32,33]. The aim of this review is to find and 
highlight the hidden but alarming data about the difficulty 
of the diagnosis and management of FM. This paper has 
also tried to show the importance of this “iceberg like con-
dition” regarding the high burden on patient and society 
with respect to life and economic impacts.
DIFFICULTLY FROM DIAGNOSIS 
TO TREATMENT
FM, often disputed and challenged, has emerged as a 
clinical syndrome with a clear cluster of symptoms and co-
morbidities [12].
Moreover, considerable overlap exists in the symptoms 
between FM and other ‘central pain’ or ‘functional so-
matic’ syndromes, such as irritable bowel syndrome, inter-
stitial cystitis/painful bladder syndrome, chronic pelvic pain, 
and temporomandibular joint disorder, as well as a number 
of psychiatric disorders, such as depression and anxiety 
[2,34,35].
While FM was originally defined by the ACR 1990 
classification criteria based on chronic widespread pain 
and tender points, the cluster of symptoms which defines 
FM goes beyond chronic widespread pain and tenderness 
[3]. The existence of polysymptomatic distress, or symp-
toms beyond body pain, constitutes a “minor” diagnostic 
criterion of the preliminary ACR 2010 diagnostic criteria 
[10]. 
Despite the ongoing tools available for screening, di-
agnosing and monitoring of this condition, there is no 
trusty agreement between experts for diagnosis and/or 
screening routes. These controversies may be related to 
ambiguous pathophysiology of FM, despite recent research 
focusing on the neurobiological mechanisms of this dis-
order [2,15]. Currently, there is no specific diagnostic labo-
ratory test or biomarker available for the diagnosis of FM 
and diagnosis was made largely by clinical judgment. The 
diagnosis of FM must be established in most cases by pri-
mary care physicians who are unfamiliar with this syn-
drome [36]. So, in addition to the absence of uniform con-
sensus about FM diagnostic criteria among experts, the 
low awareness among general physicians and even differ-
ent specialists about the diagnosis and principles of treat-
ment of this disease is disappointing [23,36-39].
A study of 172 family physicians demonstrated that 
physicians were not familiar with the diagnostic criteria for 
FM, although 96% thought that they were. They were able 
to identify the symptoms of the disorder, but were not able 
to establish the diagnosis. Only 55% of them knew that 
the syndrome is characterized by diffuse musculoskeletal 
disorders. This study also concluded continuing education 
could improve awareness and knowledge of the disorder 
[23].
Results from Choy et al. study expanded our insight 
into patients’ journey to diagnosis. At the time of this sur-
vey, patients had been experiencing FM symptoms for an 
average of 6.5 years. Based on their own recollection, pa-
tients experienced symptoms for an average of 11 months 
before presenting them to a physician. Aside from the time 
lag between first symptoms and presentation to a physi-
cian, patients recalled first presenting their FM symptoms 
to a doctor within an average of 2.3 years and presenting 
to 3.7 physicians before receiving a diagnosis [36].
Patients with FM are often referred to multiple spe-
cialists and have numerous investigations before the diag-
nosis is established [24,36,40]. It seems confusing that 
multiple symptoms compounded by limited consultation 
time may be an important factor for delaying in diagnosis. 
Also, many physicians are not aware of the ACR criteria. 
A small percentage of those who are aware of the ACR 
criteria; the ACR Criteria are not used in routine clinical 
practice likely due to some burden on the examiner and 
thoughtful interview of patients [36,40].
Delay in diagnosis can contribute to patient frus-
tration, as White et al. [28] and Annemans et al. [22] 
showed that a diagnosis of FM improves satisfaction and 
subsequently reduces healthcare costs including referrals 
and investigations.
From the point of view of treatment, in general, FM 
tends to be intractable, although symptom improvement is 
achieved in some cases. The number of drugs evaluated 
for the treatment of FM has notably increased over the 
past decade. More than 40 substances have been inves-
tigated to date, with a high variation in effectiveness and 
side effects [2]. But treatment of this syndrome is 
disappointing. Three drugs have been approved by the FDA 
for the treatment of pain in FM: pregabalin, which binds 
to a voltage­dependent, presynaptic calcium channel, and 
172 Korean J Pain Vol. 28, No. 3, 2015
www.epain.org
duloxetine and milnacipran, which selectively inhibit reup-
take of serotonin and norepinephrine, respectively. 
Although these pharmacological substances are well char-
acterized with respect to their mechanisms of action and 
binding sites, the exact location in the CNS remains to be 
fully elucidated, both from an anatomical perspective and 
with respect to receptor subtypes [2,20,41]. 
At the time of this review, FM management has fo-
cused on symptom relief and pain modification, as well as 
treatment for comorbid conditions [2,38,41]. Therefore, it 
should not come as a surprise that until revealing the uni-
fying concept of the neurobiological mechanism of FM and 
emerging of new target specific therapy, treatment of the 
disease largely relies on trial and error. 
It has been demonstrated that even after labeling FM 
diagnosis, patients have recurrent office visits and do not 
perceive their prescription medications as completely ef-
fective and express some dissatisfaction with current 
pharmacological and non-pharmacologic treatments [24,40]. 
Hughes et al. reported that, among 2,260 UK patients 
newly diagnosed with FM, there were 25 office visits, and 
11 prescriptions per patient in the year prior to diagnosis, 
and levels of healthcare utilization generally increased fol-
lowing diagnosis. This result was confirmed by Perrot et 
al. who presented that considerable healthcare utilization 
even after diagnosis indicated an unmet need for FM pa-
tients [24,40]. As such, management of FM remains an in-
effective and costly challenge for patient and physician. 
INVALIDATION AND LOW QUALITY OF LIFE
There are too many symptoms in this disorder, the 
symptoms appear too severe and too unusual, and the pa-
tients appear as being healthy when compared with pa-
tients with other pain disorders [11,12]. Due to the sub-
jective nature of symptoms and lack of physical or labo-
ratory features in fibromyalgia, patients may be faced with 
disbelief and distrust about the legitimacy of their illness 
in family and/or social interactions. This condition was re-
cently described as ‘invalidation’ [42]. Invalidation is a new 
concept in rheumatologic disorders and fibromyalgia and 
it seems to be having a high impact on patients and soci-
eties, but research on various aspects of it in fibromyalgia 
is scarce.
In many cases, both invalidation and the comorbidities 
associated with fibromyalgia impair the patient’s quality of 
life to a significant extent, culminating in loss of employ-
ment and/or withdrawal from social life [43]. Indeed, 
“discounting”, one of invalidation dimensions, correlates 
strongly with poor social and physical functioning as well 
as impaired mental health in fibromyalgia. It was also re-
vealed that negative social interactions (discounting) might 
have stronger effects on health than positive social inter-
actions (lack of understanding) [44]. So, aside from having 
a negative effect on mental well-being, invalidation could 
impact physical health and social functioning as well. It also 
decreases social support and increases social rejection 
[42]. Finally, in response to social rejection, patients may 
hide their symptoms and isolate themselves from society, 
which is likely to influence their healthcare, and in turn, 
their relationship with spouses, colleagues and medical 
care providers [45]. 
Furthermore, it was studied recently that invalidation 
can alter disease impact on health status and symptom 
severity in fibromyalgia patients. So, the more invalidation 
experienced by the patients leads to ahigher score on the 
Revised Fibromyalgia Impact Questionnaire [an instrument 
for evaluation of fibromyalgia impact on life], indicating a 
greater disease impact and the greater symptom severity 
[46,47].
Consequently, the existence of fibromyalgia cluster 
symptoms, comorbidities, difficulties in diagnosis and 
management, and patient experience of invalidation lead 
to poor quality of life; so that for almost any symptom 
characteristic or comorbid illness, the subjects with fi-
bromyalgia have SF-36 or SF-12 scores that are more ab-
normal than those of control groups [48,49]. Only patients 
with end- stage renal failure have a lower quality of life; 
and patients having other pain disorders have been identi-
fied to have better scores of quality of life than fi-
bromyalgia [10,48]. 
HIGH LEVEL OF COMORBIDITIES
As mentioned above, fibromyalgia was associated with 
high rates of many comorbid illnesses. These high rates 
may be related to the fact that fibromyalgia claimants ap-
praise their health as including more medical symptoms, 
and they value each symptom with greater importance 
than patients with other rheumatic conditions [50]. Conse-
quently, fibromyalgia patients report more frequently to 
medical services and have a higher chance for detection 
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of disorders which are either related or unrelated to their 
first complaints.
The comorbid conditions may be characterized as ex-
isting upon a continuum of painful conditions, sharing key 
symptoms or simply co-occurring with FM [16,17]. It was 
showed that one of the most commonly comorbid category 
is “other diseases of the musculoskeletal and connective 
tissue,” where 45% of FM claimants had at least one claim [16]. 
Some disorders such as hypertension, respiratory and 
other chest disorders, back disorders, abdominal pain, irri-
table bowel disorder, depression and other mental diseases 
and neoplasms were reported in fibromyalgia more fre-
quently than other conditions [16,19,20]. 
Now it is clear that the bête noire of fibromyalgia, one 
of the most common comorbidity in fibromyalgia, is a psy-
chological illness. Indeed, fibromyalgia patients experience 
psychiatric comorbidities in 30-60% [2]; this rate in-
creases when the rate of lifetime psychiatric disorders 
(commonly depression and anxiety) is considered. As often 
debated, mood disorders may aggravate and complicate 
the management of fibromyalgia, but the nature of the 
causal relationship between these two conditions is unclear 
[2,11].
Several analyses revealed the high levels of comorbid-
ities and resource utilization of fibromyalgia claimants 
[19-21,24,25,27,29-33]. Commonly visited specialists such 
as radiologists and mental health practitioners, rheumatol-
ogists and internists may further reflect unsatisfactory di-
agnosis and medical care for both physicians and patient. 
The cost of patient management in all levels of care is high 
because of the extensive work-up and disappointing 
treatment [19,21].
HIDDEN COST OF DISEASE
While all the components of total annual direct and in-
direct costs (i.e., medical utilization, receipt of prescription 
drugs, work loss, disease disability) are substantial, it esti-
mates that less than 6% of these costs were attributable 
to fibromyalgia-specific claims [19]. The studies highlight 
the wide range of illnesses and services that affect fi-
bromyalgia claimants beyond a specific diagnosis of fi-
bromyalgia [11,12,16,19-22]. 
The estimated costs of fibromyalgia presented in re-
cent studies most likely still underestimate the true burden 
of fibromyalgia on society. For example, sick time at home 
and productivity when at work were not fully measured. 
Only that part of work loss due to illness that was asso-
ciated with disability or medical care was taken into 
account. Additionally, the payments for disability reported 
in several studies reflect only a fraction of the employer’s 
total opportunity cost for workforce disruptions due to dis-
ability [29,30]. 
Other likely sources of workplace costs include reduced 
productivity, administrative and training expenses for re-
placement workers, and days missed for sick time [19,29]. 
Evaluation of fibromyalgia costs is limited to a few studies 
received recently; in these ones it was reported that for 
every dollar spent on fibromyalgia-specific healthcare costs 
for employees (i.e., medical plus prescription), the employer 
spends $57 to $143 on additional direct and indirect costs 
[19]. In other words, failure to properly account for the 
broader consequences of fibromyalgia in terms of comorbid 
conditions would result in a significant under-assessment 
of the cost of disease. On the other hand, the invalidation 
experience and poor quality of life could impair patients’ 
relationships and daily living quality and/or work effective-
ness that consequently increase immeasurable socio-
economic burden.
Thus, hidden costs of disability and comorbidities 
greatly increase the true burden of fibromyalgia [27,31]. 
Regardless of the clinical understanding of disease, when 
a claim for fibromyalgia is present, considerable costs are 
involved [19].
HIGH IN ECONOMIC BURDEN 
BUT LOW IN ATTENTION
Partially due to chronic nature of the disease, fi-
bromyalgia patients are high consumers of healthcare 
services in societies. Although present data suggests that 
the cost before diagnosis may be even higher than the cost 
after diagnosis, it showed that one would expect a con-
fident diagnosis to reduce the incidence of further diag-
nostic tests and referrals. Even so, a diagnosis, by itself, 
would not be expected to reduce symptoms and/or dis-
ability and the need for medical care [21,22,24]. 
The majority of fibromyalgia related costs are attribu-
table to lost productivity (absenteeism, presenteeism, un-
employment) and disability, which ranged from 75-88% of 
total costs. This level of social burden is higher than what 
is caused by other disorders. White et al. [29] reported that 
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FM patients missed significantly more days of work in one 
year compared with non-FM patients. Boonen et al. [25] 
also found similar results with high absenteeism and work 
loss compared with other groups.
It is estimated the mean annual measurable cost per 
patient ranged US $2,274 to $9,573 or even more than ap-
proximately $13,000 in various studies depended on se-
verity of symptoms and rout of cost calculation, In addi-
tion, it is important to note that hidden impact and costs 
of the disease can hardly be assessed; and if high im-
measurable cost is taken into account, the real economic 
impact of this complex disorder it may be appreciated  
[19,24,30,31].
The burden of illness in fibromyalgia is substantial and 
comparable to some other chronic disease such as osteo-
arthritis, rheumatoid arthritis (RA), diabetes and hyper-
tension [29,32,33]. Fibromyalgia patients incur direct costs 
approximately equal to RA patients and have more visits 
to emergency physicians, physicians, and physical therapy 
than RA patients [33]. These patients are often referred 
to for additional specialist consultations and undergo more 
diagnostic tests, but usually receive much less attention 
from the healthcare system than other chronic diseases. 
It was identified that some physicians do not want to see 
fibromyalgia patients, and the medical and lay literature 
contains many descriptions of the antagonism between 
physicians and ‘difficult’ patients with this condition [51]. 
Patients’ invalidation experience from medical systems, 
family and societies could create vicious cycle that lead to 
more and more impact to patients and societies and con-
sequently considerable clinical and economic burden.
CONCLUSIONS
This review has focused on important but less visible 
aspects of fibromyalgia with respect to the high impact of 
this disorder on patients and societies. It has emphasized 
that in spite of the benign appearance of this syndrome, 
which is known as a painful condition without injury to any 
organ of body, it has exhibited another grave “iceberg-like” 
feature with marked disability and challenges for patients 
and medical care providers. Challenges with fibromyalgia 
patients begin from making a diagnosis to manage this 
disorder, poor assessment of quality of life and experienc-
ing invalidation from people involved with patients. The 
journey of diagnosis and management of these patients 
leads to high individual and social burden through health-
care and non- healthcare pathways. Indeed, it was shown 
that direct, indirect and immeasurable costs of fi-
bromyalgia are considerable.
This alarming data highlights the urgent need for 
greater awareness of disease among medical services and 
societies. Case finding by alert general physicians and 
specialist could help avoid exhausting investigations and 
prescriptions and could consequently eliminate additional 
stress on patients and physicians due to labeled “unknown 
disease”. On the other hand, increased disease awareness 
among families and societies could lead to a better under-
standing of patients and then cost reduction. Furthermore, 
the present data emphasizes the need for future research 
focused on neurobiological mechanisms, more accurate 
routes for diagnosis and to target specific treatment of this 
illness.
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